Learn more The iShares Core High Dividend ETF (NYSEMKT: HDV) isn't as large or as popular as other dividend ETFs. As a result ...

Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they ...

That's an extremely healthy tape and we love to see it. While the gains of 2026 have obviously been in tech stocks away from ...

The tables have turned for the U.S. biosimilars market. With more than a decade since the first FDA biosim approval, strong launches to biologic copies to AbbVie’s Humira, J&J’s Stelara and ...

Samsung Bioepis, a company developing biosimilars and new drugs, announced the interim results of its phase 1 and phase 3 ...

Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism ...

The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...

A U.S. senator is pressing pharmaceutical giant Merck over its patenting and pricing practices for the blockbuster cancer drug Keytruda, escalating congressional scrutiny of industry strategies that ...

Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

The U.S. House Select Committee on China has opened investigations into five pharmaceutical companies regarding their clinical trials in China, questioning whether the drugmakers may have aided the ...